Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07620561 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Speed of Response of Lebrikizumab in High-Burden Prurigo Nodularis Patients
A Phase 2 study, sponsored by University of Maryland, Baltimore.
- Not yet
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT07620561 is a Phase 2 study that has not yet begun recruiting, run by University of Maryland, Baltimore. The registered enrollment target is 15 participants.
The verdict
NCT07620561, a Phase 2 study, has not yet begun recruiting, sponsored by University of Maryland, Baltimore.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effectiveness of lebrikizumab in treating adults with moderate-to-severe Prurigo Nodularis (PN).
Interventions
- DRUG Lebrikizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2026-06 |
| Est. Completion | 2028-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07620561
The ClinicalTrials.gov registry entry for NCT07620561 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lebrikizumab is the first listed.
NCT07620561 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07620561 about?
NCT07620561 is a clinical study titled "Efficacy and Speed of Response of Lebrikizumab in High-Burden Prurigo Nodularis Patients". The purpose of this study is to evaluate the effectiveness of lebrikizumab in treating adults with moderate-to-severe Prurigo Nodularis (PN).
What is the current status of trial NCT07620561?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2026-06. Estimated completion is 2028-03.
What interventions are being tested in trial NCT07620561?
The interventions under investigation include: Lebrikizumab (DRUG).
Who is sponsoring clinical trial NCT07620561?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.